$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-K Financial Statement

#000153217618000013 Filed on February 08, 2018

Income Statement

Concept	2017 Q4	2017 Q3	2017 Q2
Revenue	$1.582B	$1.501B	$1.470B
YoY Change	28.99%	22.99%	21.23%
Cost Of Revenue	$105.7M	$46.39M	$42.13M
YoY Change	41.5%	55.14%	2.15%
Gross Profit	$1.477B	$1.454B	$1.428B
YoY Change	28.17%	22.19%	21.91%
Gross Profit Margin	93.32%	96.91%	97.13%
Selling, General & Admin	$409.9M	$306.8M	$306.9M
YoY Change	25.77%	13.6%	5.09%
% of Gross Profit	27.76%	21.09%	21.49%
Research & Development	$528.0M	$529.7M	$510.0M
YoY Change	10.18%	-2.45%	-8.92%
% of Gross Profit	35.76%	36.43%	35.71%
Depreciation & Amortization	$34.50M	$37.80M	$35.10M
YoY Change	19.38%	35.97%	40.4%
% of Gross Profit	2.34%	2.6%	2.46%
Operating Expenses	$937.9M	$836.5M	$816.9M
YoY Change	16.49%	2.88%	-4.12%
Operating Profit	$538.8M	$559.9M	$550.3M
YoY Change	55.27%	54.33%	88.7%
Interest Expense	-$6.000M	$6.182M	$5.401M
YoY Change	76.47%	-1346.37%	-531.73%
% of Operating Profit	-1.11%	1.1%	0.98%
Other Income/Expense, Net	$22.00M	$5.679M	-$24.46M
YoY Change	-1147.62%	84.44%	-3995.22%
Pretax Income	$554.8M	$565.6M	$525.9M
YoY Change	62.46%	54.59%	79.93%
Income Tax	$55.00M	$177.3M	$138.1M
% Of Pretax Income	9.91%	31.34%	26.26%
Net Earnings	$173.5M	$388.3M	$387.7M
YoY Change	-31.45%	46.64%	97.59%
Net Earnings / Revenue	10.96%	25.88%	26.37%
Basic Earnings Per Share	$1.62	$3.64	$3.66
Diluted Earnings Per Share	$1.50	$3.32	$3.34
COMMON SHARES
Basic Shares Outstanding		106.7M shares	106.0M shares
Diluted Shares Outstanding		117.0M shares	116.1M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.410B	$1.379B	$1.268B
YoY Change	35.71%	-2.06%	21.34%
Cash & Equivalents	$812.7M	$792.1M	$744.3M
Short-Term Investments	$597.0M	$587.0M	$524.0M
Other Short-Term Assets	$437.0M	$357.0M	$381.0M
YoY Change	96.85%	99.44%	141.14%
Inventory	$726.1M	$641.6M	$554.3M
Prepaid Expenses
Receivables	$1.539B	$1.533B	$1.420B
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.335B	$4.136B	$3.860B
YoY Change	36.31%	18.11%	20.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.359B	$2.275B	$2.262B
YoY Change	13.21%	21.49%	27.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.486B	$1.327B	$1.065B
YoY Change	71.99%	70.57%	80.51%
Other Assets	$77.90M	$36.62M	$36.96M
YoY Change	283.86%	76.86%	450.45%
Total Long-Term Assets	$4.429B	$4.565B	$4.246B
YoY Change	16.77%	37.25%	41.75%
TOTAL ASSETS
Total Short-Term Assets	$4.335B	$4.136B	$3.860B
Total Long-Term Assets	$4.429B	$4.565B	$4.246B
Total Assets	$8.764B	$8.701B	$8.106B
YoY Change	25.68%	27.43%	30.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$178.2M	$154.0M	$151.0M
YoY Change	32.0%	24.19%	48.04%
Accrued Expenses	$637.0M	$538.0M	$542.0M
YoY Change	25.39%	23.68%	11.07%
Deferred Revenue	$320.1M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change	-100.0%
Total Short-Term Liabilities	$1.136B	$1.139B	$1.029B
YoY Change	-8.54%	18.46%	8.14%
LONG-TERM LIABILITIES
Long-Term Debt	$703.0M	$702.0M	$701.0M
YoY Change	99.72%	83.77%	93.65%
Other Long-Term Liabilities	$152.0M	$125.2M	$115.9M
YoY Change	51.42%	-7.72%	-3.01%
Total Long-Term Liabilities	$152.0M	$125.2M	$115.9M
YoY Change	51.42%	-7.72%	-3.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.136B	$1.139B	$1.029B
Total Long-Term Liabilities	$152.0M	$125.2M	$115.9M
Total Liabilities	$2.620B	$2.650B	$2.586B
YoY Change	3.8%	13.39%	21.48%
SHAREHOLDERS EQUITY
Retained Earnings	$2.947B	$2.773B	$2.385B
YoY Change	68.55%	85.49%	93.85%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$316.2M	$316.2M	$316.2M
YoY Change	-0.01%	0.06%	0.06%
Treasury Stock Shares	3.764M shares	3.764M shares	3.764M shares
Shareholders Equity	$6.144B	$6.052B	$5.521B
YoY Change
Total Liabilities & Shareholders Equity	$8.764B	$8.701B	$8.106B
YoY Change	25.68%	27.43%	30.64%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2017 Q2
OPERATING ACTIVITIES
Net Income	$173.5M	$388.3M	$387.7M
YoY Change	-31.45%	46.64%	97.59%
Depreciation, Depletion And Amortization	$34.50M	$37.80M	$35.10M
YoY Change	19.38%	35.97%	40.4%
Cash From Operating Activities	$566.9M	$414.9M	-$30.60M
YoY Change	45.21%	-36.27%	-107.66%
INVESTING ACTIVITIES
Capital Expenditures	-$107.6M	-$59.70M	-$54.80M
YoY Change	-28.46%	-49.66%	-60.52%
Acquisitions
YoY Change
Other Investing Activities	-$228.1M	-$299.3M	-$115.5M
YoY Change	88.82%	4.18%	-38.3%
Cash From Investing Activities	-$335.8M	-$358.8M	-$170.5M
YoY Change	23.77%	-11.58%	-47.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-210.5M	-8.200M	133.5M
YoY Change	-57.2%	-128.57%	-527.88%
NET CHANGE
Cash From Operating Activities	566.9M	414.9M	-30.60M
Cash From Investing Activities	-335.8M	-358.8M	-170.5M
Cash From Financing Activities	-210.5M	-8.200M	133.5M
Net Change In Cash	20.60M	47.90M	-67.60M
YoY Change	-105.53%	-82.51%	-259.81%
FREE CASH FLOW
Cash From Operating Activities	$566.9M	$414.9M	-$30.60M
Capital Expenditures	-$107.6M	-$59.70M	-$54.80M
Free Cash Flow	$674.5M	$474.6M	$24.20M
YoY Change	24.72%	-38.33%	-95.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	50337000000	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2015Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	50700000	USD
CY2017Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	41800000	USD
CY2016Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	28200000	USD
CY2016Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	91753000	USD
CY2017Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	120891000	USD
CY2016Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	159985000	USD
CY2017Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	194542000	USD
CY2016Q4	regn	Accumulatedamortizationofcapitalandfacilityleases Accumulatedamortizationofcapitalandfacilityleases	44000000	USD
CY2017Q4	regn	Accumulatedamortizationofcapitalandfacilityleases Accumulatedamortizationofcapitalandfacilityleases	47900000	USD
CY2017	regn	Adjustmentsrelatedtotaxwithholdingforsharebasedcompensationrestrictedstock Adjustmentsrelatedtotaxwithholdingforsharebasedcompensationrestrictedstock	100067000	USD
CY2016Q4	regn	Capitalandfacilityleaseobligationscurrent Capitalandfacilityleaseobligationscurrent	129557000	USD
CY2017Q4	regn	Capitalandfacilityleaseobligationscurrent Capitalandfacilityleaseobligationscurrent	0	USD
CY2016Q4	regn	Capitalandfacilityleaseobligationsnoncurrent Capitalandfacilityleaseobligationsnoncurrent	351569000	USD
CY2017Q4	regn	Capitalandfacilityleaseobligationsnoncurrent Capitalandfacilityleaseobligationsnoncurrent	703453000	USD
CY2015	regn	Capitalandfacilityleaseobligationsrecognized Capitalandfacilityleaseobligationsrecognized	26000000	USD
CY2016	regn	Capitalandfacilityleaseobligationsrecognized Capitalandfacilityleaseobligationsrecognized	154900000	USD
CY2017	regn	Capitalandfacilityleaseobligationsrecognized Capitalandfacilityleaseobligationsrecognized	201200000	USD
CY2016Q4	regn	Capitalandfacilityleasesatcost Capitalandfacilityleasesatcost	407100000	USD
CY2017Q4	regn	Capitalandfacilityleasesatcost Capitalandfacilityleasesatcost	724100000	USD
CY2017Q4	regn	Capitalandfacilityleasesfutureminimumleasepaymentsdue Capitalandfacilityleasesfutureminimumleasepaymentsdue	105667000	USD
CY2017Q4	regn	Capitalandfacilityleasesfutureminimumleasepaymentsdueinfiveyears Capitalandfacilityleasesfutureminimumleasepaymentsdueinfiveyears	6837000	USD
CY2017Q4	regn	Capitalandfacilityleasesfutureminimumleasepaymentsdueinfouryears Capitalandfacilityleasesfutureminimumleasepaymentsdueinfouryears	27650000	USD
CY2017Q4	regn	Capitalandfacilityleasesfutureminimumleasepaymentsduethereafter Capitalandfacilityleasesfutureminimumleasepaymentsduethereafter	0	USD
CY2017Q4	regn	Capitalandfacilityleasesfutureminimumpaymentsdueinthreeyears Capitalandfacilityleasesfutureminimumpaymentsdueinthreeyears	26257000	USD
CY2017Q4	regn	Capitalandfacilityleasesfutureminimumpaymentsdueintwoyears Capitalandfacilityleasesfutureminimumpaymentsdueintwoyears	23838000	USD
CY2017Q4	regn	Capitalandfacilityleasesfutureminimumpaymentsduenexttwelvemonths Capitalandfacilityleasesfutureminimumpaymentsduenexttwelvemonths	21085000	USD
CY2015	regn	Costofmanufacturing Costofmanufacturing	151007000	USD
CY2016	regn	Costofmanufacturing Costofmanufacturing	105070000	USD
CY2017	regn	Costofmanufacturing Costofmanufacturing	194554000	USD
CY2016Q4	regn	Costs Incurred By Landlord To Construct New Laboratory And Office Facilities CostsIncurredByLandlordToConstructNewLaboratoryAndOfficeFacilities	554181000	USD
CY2017Q4	regn	Costs Incurred By Landlord To Construct New Laboratory And Office Facilities CostsIncurredByLandlordToConstructNewLaboratoryAndOfficeFacilities	599153000	USD
CY2016Q4	regn	Deferred Revenue Excluding Amounts From Related Party Current DeferredRevenueExcludingAmountsFromRelatedPartyCurrent	116397000	USD
CY2017Q4	regn	Deferred Revenue Excluding Amounts From Related Party Current DeferredRevenueExcludingAmountsFromRelatedPartyCurrent	142392000	USD
CY2016Q4	regn	Deferred Revenue Excluding Amounts From Related Party Non Current DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent	327298000	USD
CY2017Q4	regn	Deferred Revenue Excluding Amounts From Related Party Non Current DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent	249263000	USD
CY2016Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	115267000	USD
CY2017Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	177746000	USD
CY2016Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	503474000	USD
CY2017Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	379936000	USD
CY2015	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	477000	shares
CY2016	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	474000	shares
CY2017	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	484000	shares
CY2015	regn	Interestexpenseinconnectionwithcapitalandfacilityleases Interestexpenseinconnectionwithcapitalandfacilityleases	9700000	USD
CY2016	regn	Interestexpenseinconnectionwithcapitalandfacilityleases Interestexpenseinconnectionwithcapitalandfacilityleases	5400000	USD
CY2017	regn	Interestexpenseinconnectionwithcapitalandfacilityleases Interestexpenseinconnectionwithcapitalandfacilityleases	19500000	USD
CY2016Q4	regn	Facility Purchase Price FacilityPurchasePrice	720000000	USD
CY2017Q1	regn	Initialtermoflease Initialtermoflease	P5Y
	regn	Loss Contingency Damages Soughtperunitproduced. LossContingencyDamagesSoughtperunitproduced.	10000	EUR
CY2016Q4	regn	Paymenttowardspurchasepriceof Tarrytownfacility PaymenttowardspurchasepriceofTarrytownfacility	57000000	USD
CY2017Q1	regn	Potentialextendedtermoflease Potentialextendedtermoflease	P5Y
CY2017Q1	regn	Tarrytownfacilitycapitalandfacilityleaseobligations Tarrytownfacilitycapitalandfacilityleaseobligations	720000000	USD
CY2017Q4	regn	Maximumsharesthecollaboratorcouldsell Maximumsharesthecollaboratorcouldsell	1400000	shares
CY2015	regn	Maximumamountofwarrantpayable Maximumamountofwarrantpayable	-23317000	USD
CY2017	regn	Numberofdemandrightstorequirethe Companytoconductregisteredunderwrittenpublicoffering NumberofdemandrightstorequiretheCompanytoconductregisteredunderwrittenpublicoffering	3
CY2015	regn	Other Collaboration Revenue OtherCollaborationRevenue	580488000	USD
CY2016	regn	Other Collaboration Revenue OtherCollaborationRevenue	744270000	USD
CY2017	regn	Other Collaboration Revenue OtherCollaborationRevenue	938052000	USD
CY2017Q1	regn	Reimbursementreceivedbythe Company ReimbursementreceivedbytheCompany	57000000	USD
CY2016Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	175263000	USD
CY2017Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	242014000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	879096000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	815078000	USD
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	134984000	USD
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	178183000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1343368000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1538642000	USD
CY2016Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	92989000	USD
CY2017Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	193684000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	425504000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	566294000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12840000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	640000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3029993000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3512833000	USD
CY2015	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	405317000	USD
CY2015	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	160538000	USD
CY2016	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	143182000	USD
CY2017	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	201621000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	819657000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	47789000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-449456000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-643365000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	464022000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	574887000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	524534000	USD
CY2015	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	694724000	USD
CY2016	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	577874000	USD
CY2017	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	108601000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2016Q4	us-gaap	Assets Assets	6973466000	USD
CY2017Q4	us-gaap	Assets Assets	8764286000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	3180188000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	4335030000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	1367741000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	2083341000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6241000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8804000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18987000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8926000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	1380487000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2083463000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	58000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3583000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	18987000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	8926000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	920357000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	1370760000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	18929000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	5343000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	883950000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	1044084000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	36407000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	326676000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	815041000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1426773000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	503481000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	593783000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1318522000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2020556000	USD
CY2016Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	1278283000	USD
CY2017Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	1441565000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	648719000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	809102000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	535203000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	812733000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	160383000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-273899000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	277530000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	592377000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	874110000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1211991000	USD
CY2016Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	318929000	USD
CY2017Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	408857000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	241702000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	194624000	USD
CY2017	us-gaap	Cost Of Goods Sold CostOfGoodsSold	202507000	USD
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	2851812000	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	686561000	USD
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	3529686000	USD
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	3792636000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	786964000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	560250000	USD
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4004000	USD
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-1362000	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4827000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	719133000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	794371000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	560991000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	28568000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8769000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-4086000	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-119849000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-377368000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	317064000	USD
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-6475000	USD
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	3859000	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	3203000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-130092000	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-360078000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	319009000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9275000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	47696000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	231664000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	320138000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	830772000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	629199000	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3768000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	13431000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1258000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	214587000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	102441000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	837998000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	558174000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	825303000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	506291000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	825303000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	506291000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	834578000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	553987000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	49100000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	26387000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	21139000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	515984000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	391034000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	37188000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	38312000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3420000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4187000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	9275000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	3067000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	44629000	USD
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	15400000	USD
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	17700000	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	19600000	USD
CY2015	us-gaap	Depreciation Depreciation	74900000	USD
CY2016	us-gaap	Depreciation Depreciation	104700000	USD
CY2017	us-gaap	Depreciation Depreciation	142200000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	74909000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	104745000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	145467000	USD
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.17
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.74
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.88
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.53
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.41
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	8.55
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.36
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.66
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.64
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.62
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	11.27
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.52
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.59
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.69
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.27
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.19
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.70
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.16
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.34
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.32
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.50
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	10.34
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.481
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.327
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.423
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.020
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.019
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.017
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.032
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.028
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.026
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.122
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.088
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.007
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.028
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.006
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.020
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.109
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.090
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.009
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.013
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.001
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.016
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.012
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.013
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	153086000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	191825000	USD
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	405317000	USD
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2017	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2016Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2017Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2016Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	44100000	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0	USD
CY2016Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	152525000	USD
CY2017Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	179968000	USD
CY2017Q3	us-gaap	Gain Loss On Interest Rate Cash Flow Hedge Ineffectiveness GainLossOnInterestRateCashFlowHedgeIneffectiveness	0	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	18861000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1225097000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1329815000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2078511000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	589041000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	434293000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	880000000	USD
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	276092000	USD
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	481360000	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	754843000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	303657000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	253980000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-23188000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	491421000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	143827000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	362720000	USD
CY2015	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	121623000	USD
CY2016	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	360078000	USD
CY2017	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-318809000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	608892000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	244270000	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-113099000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	111825000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	149776000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	314195000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	79476000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-23543000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	113331000	USD
CY2015	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2246000	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	936000	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	61000	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9446000	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	10177000	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9132000	shares
CY2015	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-14241000	USD
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-7195000	USD
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-25119000	USD
CY2015	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2016	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	397000	USD
CY2017	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2015	us-gaap	Interest Paid Net InterestPaidNet	10582000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	5454000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	18678000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13334000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	21791000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	399356000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	726138000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	92287000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	190045000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	202301000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	302042000	USD
CY2016Q4	us-gaap	Land Land	103906000	USD
CY2017Q4	us-gaap	Land Land	192757000	USD
CY2016Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	101101000	USD
CY2017Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	102599000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	2524221000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	2620208000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6973466000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8764286000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1241495000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1135483000	USD
	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	10000000	EUR
CY2017	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	10000000	EUR
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	503481000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	596847000	USD
CY2016Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	864260000	USD
CY2017Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1486494000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-262796000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-700391000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-24400000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-907601000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1046904000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1005182000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1330780000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1473396000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1307112000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	636056000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	181385000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	196218000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	264804000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	253115000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	895522000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	248931000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	387744000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	388317000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	173519000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	1198511000	USD
CY2015	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	636056000	USD
CY2016	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	895919000	USD
CY2017	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	1198511000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26819000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-926000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1080000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	1251916000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	1330741000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	2079591000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	21878000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	8963000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1927000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2431000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3139000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3912000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1506000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	15202000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	16713000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4289000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	103512000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	129410000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20294000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	77866000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-43679000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-21412000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	13480000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	24900000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	0	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	765000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-43679000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-21412000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	12715000	USD
CY2016Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	91434000	USD
CY2017Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	212260000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1178000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	267000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	100385000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	152073000	USD
CY2015	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-52562000	USD
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-45139000	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-63581000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12578000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6269000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	24039000	USD
CY2015	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	74889000	USD
CY2016	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	119102000	USD
CY2017	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	338519000	USD
CY2015	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	573487000	USD
CY2016	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	643365000	USD
CY2017	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2015	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	160537000	USD
CY2016	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	143182000	USD
CY2017	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	301688000	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	557105000	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	809419000	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1277140000	USD
CY2015	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	677933000	USD
CY2016	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	511941000	USD
CY2017	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	272626000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	130528000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	224972000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	206358000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	126739000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	240213000	USD
CY2015	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	27373000	USD
CY2016	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	5085000	USD
CY2017	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	57000000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	327437000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	274456000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	544584000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2508925000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2924899000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2083421000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2358605000	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2017	us-gaap	Realized Gain Loss On Marketable Securities Cost Method Investments And Other Investments RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments	8300000	USD
CY2015	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	166467000	USD
CY2015	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	166500000	USD
CY2016	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	12900000	USD
CY2016	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	12894000	USD
CY2017	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2015	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	1353000	USD
CY2016	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	32774000	USD
CY2017	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	19925000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1620577000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2052295000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2075142000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1748222000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2946733000	USD
CY2015	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	758873000	USD
CY2016	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	658665000	USD
CY2017	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	877193000	USD
CY2015	us-gaap	Revenues Revenues	4103728000	USD
CY2016Q1	us-gaap	Revenues Revenues	1200849000	USD
CY2016Q2	us-gaap	Revenues Revenues	1212629000	USD
CY2016Q3	us-gaap	Revenues Revenues	1220122000	USD
CY2016Q4	us-gaap	Revenues Revenues	1226827000	USD
CY2016	us-gaap	Revenues Revenues	4860427000	USD
CY2017Q1	us-gaap	Revenues Revenues	1318991000	USD
CY2017Q2	us-gaap	Revenues Revenues	1470116000	USD
CY2017Q3	us-gaap	Revenues Revenues	1500673000	USD
CY2017Q4	us-gaap	Revenues Revenues	1582447000	USD
CY2017	us-gaap	Revenues Revenues	5872227000	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2689478000	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3338390000	USD
CY2017	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3718463000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	838526000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1177697000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1320433000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	459049000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	559878000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	507277000	USD
CY2015	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1625113	shares
CY2016	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	121058	shares
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	818360000	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	48004000	USD
CY2015	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	15382000	USD
CY2016	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	16561000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	19416000	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	215462000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	115182000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	240580000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	2550251000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	3654837000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	4449245000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	6144078000	USD
CY2016Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	235776000	USD
CY2017Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	227000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3763868	shares
CY2017Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3763868	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	316240000	USD
CY2017Q4	us-gaap	Treasury Stock Value TreasuryStockValue	316240000	USD
CY2015	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2016	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	57615000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	116572000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	117166000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	146158000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	2697000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	14430000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	59909000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	45575000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	49028000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-952000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-42284000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-5606000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	102100000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	107200000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	146200000	USD
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24781000	USD
CY2015Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	55249000	USD
CY2016Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	45851000	USD
CY2017Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	85302000	USD
CY2015	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	193190000	USD
CY2016	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	278304000	USD
CY2017	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	408270000	USD
CY2015	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	162722000	USD
CY2016	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	287702000	USD
CY2017	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	368819000	USD
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2015	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12169000	shares
CY2016	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	11648000	shares
CY2017	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9616000	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115230000	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116367000	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115954000	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103061000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104719000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106338000	shares
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, certain financial instruments, and accounts receivable. A large portion of the Company's cash is held by a few major financial institutions. In accordance with the Company's policies, the Company mandates asset diversification and monitors exposure with its counterparties. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concentrations of credit risk with respect to accounts receivable are significant. The Company has a concentration of credit risk associated with the receivables due from its collaborators Bayer, Sanofi, and Teva. The Company is also subject to credit risk with accounts receivable from its product sales of EYLEA and ARCALYST, which are due from several distributors and specialty pharmacies (the Company's customers). As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, three individual customers accounted for </font><font style="font-family:inherit;font-size:10pt;">99%</font><font style="font-family:inherit;font-size:10pt;"> of the Company's net trade accounts receivable balances. The Company has contractual payment terms with each of its customers, and the Company monitors its customers' financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. In addition, the Company may insure a portion of its accounts receivables within its overall risk management practices. As of December 31, 2017 and 2016, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> reserves against trade accounts receivable. In addition, during the years ended December 31, 2017, 2016, and 2015, the Company did </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">t recognize any charges for write-offs of trade accounts receivable. </font></div></div>
CY2017	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenue consists of U.S. sales of EYLEA and ARCALYST. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, collection from the customer is reasonably assured, the Company has no further performance obligations, and returns can be reasonably estimated. The Company's written contracts with its customers stipulate product is shipped freight on board destination (FOB destination). The Company records revenue from product sales upon delivery to its customers. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells EYLEA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">in the United States to several distributors and specialty pharmacies. The Company sells ARCALYST in the United States to specialty pharmacies. Under these distribution models, the distributors and specialty pharmacies generally take physical delivery of product. For EYLEA, the distributors and specialty pharmacies generally sell the product directly to healthcare providers, whereas for ARCALYST, the specialty pharmacies sell the product directly to patients. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental and other programs, distribution-related fees, and other sales-related deductions. Calculating these provisions involves estimates and judgments. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government Rebates and Chargebacks: </font><font style="font-family:inherit;font-size:10pt;">The Company estimates reductions to product sales for Medicaid and Veterans' Administration ("VA") programs, and for certain other qualifying federal and state government programs. Based upon the Company's contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, and estimated payer mix, the Company estimates and records an allowance for rebates and chargebacks. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, and invoices received for claims from prior quarters that have not been paid. The Company's reserves related to discounted pricing to VA, Public Health Services ("PHS"), and other institutions (collectively "qualified healthcare providers") represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies). The Company's customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distribution-Related Fees: </font><font style="font-family:inherit;font-size:10pt;">The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers generally based on gross sales. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns: </font><font style="font-family:inherit;font-size:10pt;">Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. The Company will accept returns for three months prior to and up to six months after the product expiration date. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, inventory levels in the distribution channel, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers of EYLEA to healthcare providers and ARCALYST to patients using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Estimates which could have a significant impact on the Company's financial statements include provisions related to product sales, such as rebates, chargebacks, and distribution-related fees; periods over which payments, including non-refundable up-front, license, and milestone payments, are recognized as revenue in connection with collaboration and other agreements; periods over which certain clinical trial costs are recognized; fair value of stock options; inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value; capitalization of inventory costs associated with the Company's products prior to regulatory approval; provisions for loss contingencies; deferred tax asset valuation allowances; the assessment of uncertain tax positions; and the provisional amount recorded in connection with the enactment of tax laws (see Note 16). </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the Company's collaborations with Sanofi and Bayer:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in Sanofi collaboration revenue is the Company's share of profits or losses from commercialization of antibodies, which is provided by Sanofi, and includes an estimate of the Company's share of profits or losses for the most recent fiscal quarter.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in Bayer collaboration revenue is the Company's share of profits or losses from commercialization of EYLEA outside the United States, which is provided by Bayer, and includes an estimate of the Company's share of profits or losses for the most recent fiscal quarter.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in research and development expenses is the Company's share of development expenses incurred by Bayer and Sanofi, including the Company's share of Bayer and Sanofi estimated development expenses for the most recent fiscal quarter.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These estimates for the most recent period are adjusted on a prospective basis, if necessary, in the subsequent period to reflect actual amounts. </font></div></div>

Files In Submission

Name	View Source	Status
R52.htm	Edgar Link	pending
0001532176-18-000013-index-headers.html	Edgar Link	pending
0001532176-18-000013-index.html	Edgar Link	pending
0001532176-18-000013.txt	Edgar Link	pending
0001532176-18-000013-xbrl.zip	Edgar Link	pending
chart-ca959e8b4b155777814.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-123117x10k.htm	Edgar Link	pending
regn-20171231.xml	Edgar Link	completed
regn-20171231.xsd	Edgar Link	pending
regn-20171231_cal.xml	Edgar Link	unprocessable
regn-20171231_def.xml	Edgar Link	unprocessable
regn-20171231_lab.xml	Edgar Link	unprocessable
regn-20171231_pre.xml	Edgar Link	unprocessable
regn-ex_10211xar2014ltipnq.htm	Edgar Link	pending
regn-ex_10212xar2014ltipis.htm	Edgar Link	pending
regn-ex_10213xar2014ltipnq.htm	Edgar Link	pending
regn-ex_10214xar2014ltipis.htm	Edgar Link	pending
regn-ex_10215xar2014ltiprs.htm	Edgar Link	pending
regn-ex_10216xar2014ltipnq.htm	Edgar Link	pending
regn-ex_211x12312017x10k.htm	Edgar Link	pending
regn-ex_231x12312017x10k.htm	Edgar Link	pending
regn-ex_311x12312017x10k.htm	Edgar Link	pending
regn-ex_312x12312017x10k.htm	Edgar Link	pending
regn-ex_32x12312017x10k.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2017 Q4 Form 10-K Financial Statement

#000153217618000013 Filed on February 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2017 Q4 Form 10-K Financial Statement

#000153217618000013 Filed on February 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn